大摩对该公司的基本假设认为，预计2025年及以后年销售额将稳定在约40亿元人民币或以上。智通财经APP获悉，摩根士丹利发布研报称，上调东阳光长江药业(01558)目标价11.1%，从12.6港元升至14港元，维持“增持”评级。大摩指，将2027-2030年盈利预测上调2-11%，对该公司的基本假设认为，预计2025年及以后年销售额将稳定在约40亿元人民币或以上。
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.